<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03739112</url>
  </required_header>
  <id_info>
    <org_study_id>CP-PRO-QVLP-014</org_study_id>
    <nct_id>NCT03739112</nct_id>
  </id_info>
  <brief_title>Efficacy of a Plant-derived Quadrivalent VLP Vaccine in the Elderly</brief_title>
  <official_title>A Randomized, Observer-blind, Active Comparator-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-derived Quadrivalent VLP Influenza Vaccine in Adults 65 Years of Age and Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicago</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 3 study is intended to assess the relative efficacy of the Quadrivalent VLP
      Influenza Vaccine during the 2018-2019 influenza season compared to a licensed vaccine in
      elderly adults 65 years of age and older. One dose of Quadrivalent Virus-Like Particles (VLP)
      Influenza Vaccine (30 μg/strain) or of Comparator (15 ug/strain) will be administered to
      approximately 12,120 subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, observer-blind, active-controlled multicenter, Phase 3 study will be
      conducted at multiple sites. The composition of the Quadrivalent VLP Influenza Vaccine to be
      used in this study includes a mix of recombinant H1, H3, and two B hemagglutinin proteins
      expressed as VLPs for the 2018-2019 influenza virus strains.

      Approximately 12,120 healthy male and female subjects aged 65 years and older will be
      randomized in a 1:1 ratio into one of two parallel treatment groups, such that approximately
      6,060 subjects will receive the Quadrivalent VLP Influenza Vaccine at a dose of 30 μg/strain
      and approximately 6,060 subjects will receive the comparator. Within the two treatment
      groups, subjects will be stratified by site and two age groups (65-74 years of age and 75
      years of age and older in a 2:1 ratio).

      Subjects will participate in this study for approximately eight to ten months, during which a
      first visit will be scheduled on Day 0 for screening and vaccine administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2018</start_date>
  <completion_date type="Actual">June 14, 2019</completion_date>
  <primary_completion_date type="Actual">May 17, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a randomized, observer-blind, active comparator-controlled, multicenter, Phase 3 efficacy study.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Surveillance personnel is blinded from IP injection</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of protocol-defined Influenza-Like Illnesses (ILI) cause by any influenza viral type/subtype</measure>
    <time_frame>8 months</time_frame>
    <description>Occurrences of protocol-defined ILI due to laboratory-confirmed influenza viral type/sub-type (RT-PCR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of ILI cause by vaccine-matched strains</measure>
    <time_frame>8 months</time_frame>
    <description>Occurrences of laboratory-confirmed ILI caused by influenza viral types/subtypes that are matched (and/or antigenically similar) to the strains covered in the vaccination formulation (RT-PCR and serotyping)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of protocol-defined Respiratory Illnesses (RI) cause by vaccine-matched strains</measure>
    <time_frame>8 months</time_frame>
    <description>Occurrences of laboratory-confirmed RI caused by vaccine-matched strains sequential RT-PCR and serotyping)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of protocol-defined Respiratory Illnesses (RI) cause by any influenza viral types/subtypes</measure>
    <time_frame>8 months</time_frame>
    <description>Occurrences of laboratory-confirmed RI caused by any influenza viral types/subtypes (sequential RT-PCR and serotyping)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrences of ILI regardless of laboratory results</measure>
    <time_frame>8 months</time_frame>
    <description>Occurrences of ILI post vaccination confirmed or not by laboratory testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (Adverse Events)</measure>
    <time_frame>8 months</time_frame>
    <description>The number of participants with solicitated local and systemic reactions within 15 minutes post-vaccination, solicitated reactions up to seven days poat-vaccination, unsolicited AEs up to 21 days post-vaccination and Serious Adverse Events (SAE), New Onset of Chronic Disease (NOCD) and adverse events leading to withdrawal up to the end of surveillance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>21 days after injection</time_frame>
    <description>To measure, in a subset of 420 subjects, the immunogenicity of a single dose of Quadrivalent VLP Influenza Vaccine given at a dose of 30 μg/strain or comparator, as measured by hemagglutination inhibition (HI) assay, microneutralization (MN) assay, and single radial hemolysis (SRH) assay against homologous and heterologous (HI only) influenza strains.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12793</enrollment>
  <condition>Virus Diseases</condition>
  <condition>RNA Virus Infections</condition>
  <condition>Respiratory Tract Diseases</condition>
  <condition>Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>Quadrivalent VLP Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose - 30 µg/strain of Quadrivalent VLP Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quadrivalent Comparator Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose - 15 ug/strain of Quadrivalent Comparator Vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent VLP Vaccine</intervention_name>
    <description>Single dose of a 30 µg/strain of Quadrivalent VLP Vaccine</description>
    <arm_group_label>Quadrivalent VLP Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent Comparator Vaccine</intervention_name>
    <description>Single dose of a 15 ug/strain of Quadrivalent Comparator Vaccine</description>
    <arm_group_label>Quadrivalent Comparator Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must have read, understood, and signed the informed consent form (ICF) prior
             to participating in the study; subjects must also complete study-related procedures
             and communicate with the study staff at visits and by phone during the study;

          2. Subject must have a body mass index (BMI) ≤ 35 kg/m2;

          3. Subjects are considered by the Investigator to be reliable and likely to cooperate
             with the assessment procedures and be available for the duration of the study;

          4. Male and female subjects must be 65 years of age and older at the
             Screening/Vaccination visit (Visit 1);

          5. Subjects must be non-institutionalized (e.g. not living in rehabilitation centres or
             old-age homes; living in an elderly community is acceptable) and have no acute or
             evolving medical problems prior to study participation and no clinically relevant
             abnormalities that could jeopardize subject safety or interfere with study
             assessments, as assessed by the Principal Investigator or sub-Investigator (thereafter
             referred as Investigator) and determined by medical history, physical examination, and
             vital signs;

        Note: Subjects with a pre-existing chronic disease will be allowed to participate if the
        disease is stable and, according to the Investigator's judgment, the condition is unlikely
        to confound the results of the study or pose additional risk to the subject by
        participating in the study. Stable disease is generally defined as no new onset or
        exacerbation of pre-existing chronic disease three months prior to vaccination. Based on
        the Investigator's judgment, a subject with more recent stabilization of a disease could
        also be eligible.

        Exclusion Criteria:

          1. According to the Investigator's opinion, history of an ongoing acute or evolving
             medical or neuropsychiatric illness. 'Evolving' is defined as:

               -  Requiring a new medical or surgical treatment during the three months prior to
                  study vaccine administration unless the criteria outlined in inclusion criterion
                  no. 5 can be met (i.e. the Investigator can justify inclusion based upon the
                  innocuous nature of medical/surgical events and/or treatments);

               -  Requiring any significant change in a chronic medication (i.e. drug, dose,
                  frequency) during the three months prior to study vaccine administration due to
                  uncontrolled symptoms or drug toxicity unless the innocuous nature of the
                  medication change meets the criteria outlined in inclusion criterion no. 5 and is
                  appropriately justified by the Investigator.

          2. Any medical or neuropsychiatric condition or any history of excessive alcohol use or
             drug abuse that would render the subject unable to provide informed consent or unable
             to provide valid safety observations and reporting, including methadone (methadone as
             treatment for opioid dependence may be acceptable if the subject has been otherwise
             opioid-free for at least three years);

          3. Any autoimmune disease other than hypothyroidism on stable replacement therapy
             (including, but not limited to rheumatoid arthritis, systemic lupus erythematosus,
             Crohn's disease, type 1 diabetes, and inflammatory bowel disease) or any confirmed or
             suspected immunosuppressive condition or immunodeficiency including known or suspected
             human immunodeficiency virus (HIV), Hepatitis B or C infection, the presence of
             lymphoproliferative disease;

          4. Any history of status asthmaticus or ongoing serious problems with asthma,
             hospitalization for asthma control, or recurrent asthma episodes requiring medical
             attention in the last three years (one or more episodes per year);

          5. Administration or planned administration of any non-influenza vaccine within 30 days
             prior to randomization up to blood sampling on Day 21. Immunization on an emergency
             basis will be evaluated case-by-case by the Investigator;

          6. Administration of any adjuvanted or investigational influenza vaccine within one year
             prior to randomization or planned administration prior to the completion of the study;

          7. Administration of any 'standard', non-adjuvanted influenza vaccine (e.g. live
             attenuated trivalent/quadrivalent inactivated influenza vaccine or split
             trivalent/quadrivalent inactivated influenza vaccine administered by intranasal,
             intradermal, or intramuscular [IM] route) within six months prior to randomization and
             up to completion of the study;

          8. Use of any investigational or non-registered product within 30 days or five
             half-lives, whichever is longer, prior to randomization or planned use during the
             study period. Subjects may not participate in any other investigational or marketed
             drug study while participating in this study until after the study;

          9. Treatment with systemic glucocorticoids at a dose exceeding 10 mg of prednisone (or
             equivalent) per day for more than seven consecutive days or for ten or more days in
             total, within one month of study vaccine administration; any other cytotoxic or
             immunosuppressant drug, or any immunoglobulin preparation within three months of
             vaccination and until the completion of the study. Low doses of nasal or inhaled
             glucocorticoids are allowed. Topical steroids are permitted;

         10. Any significant disorder of coagulation including, but not limited to, treatment with
             warfarin derivatives or heparin. Persons receiving prophylactic anti-platelet
             medications (e.g. low-dose aspirin [no more than 100 mg/day]), and without a
             clinically apparent bleeding tendency are eligible. Subjects treated with new
             generation drugs that do not increase the risk of IM bleeding (e.g. clopidogrel) are
             also eligible;

         11. History of allergy to any of the constituents of the Quadrivalent VLP Influenza
             Vaccine, any components of the active comparator quadrivalent vaccine, or tobacco;

         12. History of anaphylactic allergic reactions to plants or plants components (including
             fruits and nuts);

         13. Use of antihistamines within 48 hours prior to study vaccination;

         14. Daily use of large doses of medication for pain control or inflammation (e.g. opioids,
             nonsteroidal anti-inflammatory drugs [NSAIDs]). Use of a singular regular dose either
             in the morning or at bedtime would not be exclusionary;

         15. Use of prophylactic medications (e.g. acetaminophen/paracetamol, aspirin, naproxen, or
             ibuprofen) within 24 hours of randomization to prevent or pre-empt symptoms due to
             vaccination;

         16. Planned use of influenza antiviral treatment medication before the collection of NP
             swabs (e.g. oseltamivir, zanamivir, rapivab);

         17. Have a rash, dermatological condition, tattoos, muscle mass, or any other
             abnormalities at the injection site that may interfere with injection site reaction
             rating;

         18. Subjects who have received a blood transfusion within 90 days prior to study
             vaccination;

         19. Subjects with abnormal vital signs (systolic blood pressure [BP] ≥ 150 mmHg and/or
             diastolic BP ≥ 95 mmHg for individuals taking antihypertensive medication and ≥ 140
             mmHg and/or diastolic BP ≥ 90 mmHg for individuals not taking antihypertensive
             medication; heart rate [HR] ≤ 45 beats/min and ≥ 100 beats/min) evaluated by an
             Investigator to be clinically significant. A subject with abnormal vital signs results
             may be included in the study based on Investigator's judgment (e.g. a resting HR ≤ 45
             in highly trained athletes);

         20. Presence of any febrile illness (including an oral temperature [OT] ≥ 38.0 ˚C within
             24 hours prior to vaccination;

         21. Cancer or treatment for cancer within three years prior to study vaccine
             administration. Persons with a history of cancer who are disease-free without
             treatment for three years or more are eligible. However, individuals with conditions
             such as treated and uncomplicated basal cell carcinoma of the skin or non-treated,
             non-disseminated local prostate cancer may be eligible;

         22. Subjects identified as an Investigator or employee of the Investigator or clinical
             site with direct involvement in the proposed study, or identified as an immediate
             family member (i.e. parent, spouse) of the Investigator or any employee of Medicago
             (or their family members);

         23. Subjects with a history of Guillain-Barré Syndrome.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sébastien Soucy</last_name>
    <role>Study Chair</role>
    <affiliation>Director, Clinical Studies</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian Ward</last_name>
    <role>Study Director</role>
    <affiliation>Medical Officer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>(Site 225) Coastal Clinical Research</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 201) Clinical Research Consortium</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 213) Advanced Clinical Research</name>
      <address>
        <city>Banning</city>
        <state>California</state>
        <zip>92220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 246) Paradigm Clinical Research / Pharmaseek</name>
      <address>
        <city>Redding</city>
        <state>California</state>
        <zip>96001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 212) Benckmark Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95864</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 244) Paradigm Clinical Research Center Inc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 242) Paradigm Clinical Research Centers Inc</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 239) Alliance for Multispeciality Research</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 222) Research Centers of America</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 221) St-Johns Center for Clinical Research</name>
      <address>
        <city>Ponte Vedra</city>
        <state>Florida</state>
        <zip>32081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 231) QPS-MRA LLC</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 251) Meridian Clinical Research</name>
      <address>
        <city>Richmond Hill</city>
        <state>Georgia</state>
        <zip>31324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 240) Meridian Clinical Research LLC</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 223) Clinical Research Atlanta</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 249) Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 219) Heartland Research Associates LLC</name>
      <address>
        <city>Augusta</city>
        <state>Kansas</state>
        <zip>67010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 234) Heartland Research Associates LLC</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 215) Heartland Research Associates LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 235) Heartland Research Associates LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 241) Central Kentucky Reserach Associates</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 203) Benchmark Research</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 227) Sundande Clinical Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 226) Meridian Clinical Research LLC</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>68701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 211) Meridian Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 209) United Medical Associates</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 217) Regional Clinical Research inc</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 237) PMG Research of Cary LLC</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 230) PMG Research of Charlotte LLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 205) PMG Research of Rocky Mount LLC</name>
      <address>
        <city>Rocky Mount</city>
        <state>North Carolina</state>
        <zip>27804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 236) PMG Research</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 228) Research of Winston-Salem</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 233) Sterling Research Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 208) Sterling Research Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 245) Rapid Medical Research</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 202) Aventiv Research Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 207) Lynn Institute of Norman</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 238) Tekton Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 216) PMG Research of Charleston LLC</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 248) Coastal Carolina Research Center</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 201) Meridian Clinical Research</name>
      <address>
        <city>Dakota Dunes</city>
        <state>South Dakota</state>
        <zip>57049</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 247) New orleans Center for Clinical Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 206) Benchmark Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 218) Tekton Research Inc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 214) Ventavia Research Group LLC</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 224) Benchmark Research</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 232) Benchmark Research</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 250) Clinical Trials of Texas Inc</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 204) Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 220) Advanced Clinical Research</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 229) Clinical Research Associates of Tidewater</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 106) Colchester Research Group</name>
      <address>
        <city>Truro</city>
        <state>Nova Scotia</state>
        <zip>B2N 1L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 113) Dawson Road Family Medical Clinic</name>
      <address>
        <city>Guelph</city>
        <state>Ontario</state>
        <zip>N1H 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 110) Manna Research Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 103) Q &amp; T Recherche Chicoutimi</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 7Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 105) Q &amp; T Outaouais</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8Y 6S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 107) Manna Research Inc.</name>
      <address>
        <city>Levis</city>
        <state>Quebec</state>
        <zip>G6W 0M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 109) Manna Research Inc. (Mirabel)</name>
      <address>
        <city>Mirabel</city>
        <state>Quebec</state>
        <zip>J7J 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 108) Manna Research</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 102) CHU de Québec - Université Laval</name>
      <address>
        <city>Québec City</city>
        <state>Quebec</state>
        <zip>G1E 7G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(site 101) Centre de Recherche St-Louis</name>
      <address>
        <city>Québec City</city>
        <state>Quebec</state>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 110) Alpha Recherche Clinique</name>
      <address>
        <city>Québec City</city>
        <state>Quebec</state>
        <zip>G3K 2P8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 104) Q &amp; T Recherche Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1J 2G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 112) Medexa Recherche</name>
      <address>
        <city>Victoriaville</city>
        <state>Quebec</state>
        <zip>G6P 6P6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 309) Espoo Vaccine Research Clinic</name>
      <address>
        <city>Espoo</city>
        <zip>02230</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 303) Helsinki South Vaccine Research Clinic</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 308) Helsinki East Vaccine Research Center</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 301) Jarvenpaa Vaccine Research Clinic</name>
      <address>
        <city>Järvenpää</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 306) Kokkola Vaccine Research Clinic</name>
      <address>
        <city>Kokkola</city>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 304) Oulu Vaccine Research Clinic</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 302) Tampere University Vaccine Research Center</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 305) Seinaejoki Vaccine Research Clinic</name>
      <address>
        <city>Seinäjoki</city>
        <zip>60100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 310) Tampere Vaccine Research Clinic</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 307) Turku Vaccine Research Center</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 410) Emovis GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10629</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 418) Klinische Forschung Berlin GbR</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 422) Synexus Clinical Research GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>12627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 402) Synexus Clinical research GmbH</name>
      <address>
        <city>Bochum</city>
        <zip>44787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 409) Gemeinschaftspraxis Dr. med Kleinecke-Pohl</name>
      <address>
        <city>Cologne</city>
        <zip>51069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 401) Cardiologicum Dresden &amp; Pirna</name>
      <address>
        <city>Dresden</city>
        <zip>01277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 406) Diabetologische Germeinschafts praxis Faulman</name>
      <address>
        <city>Dresden</city>
        <zip>1279</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 405) Doktor Markus Faghih</name>
      <address>
        <city>Essen</city>
        <zip>45355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 407) Klinisches Forschungszentrum Dr. Hagemann am Hausarztzer</name>
      <address>
        <city>Essen</city>
        <zip>45355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 417) Medizentrum Essen-Borbeck</name>
      <address>
        <city>Essen</city>
        <zip>45355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 414) Unterfrintroper Hausarztzentrum Klinische Forschung</name>
      <address>
        <city>Essen</city>
        <zip>45359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(SIte 404) Synexus Clinical Reserach GmbH</name>
      <address>
        <city>Frankfurt</city>
        <zip>60313</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 411) MedicoKIT GmbH</name>
      <address>
        <city>Goch</city>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 425) Clinical Research Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 403) Praxis Dr. Med Cornelia Brauer</name>
      <address>
        <city>Hamburg</city>
        <zip>22415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 408) Germeinsschaftspraxis Dr. med Christiane Klein/Minnich</name>
      <address>
        <city>Künzing</city>
        <zip>94550</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 421) SIBAmed Studienzentrum GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>01403</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 420) Synexus Clinical Research GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 423) centrum fuer Diagnostik und Gesundheit</name>
      <address>
        <city>Munich</city>
        <zip>80809</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 413) Dr. Ingomar F.K. Naudts MD Office</name>
      <address>
        <city>Rodgau</city>
        <zip>63110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 415) Praxisgemeinschaft Stuhr-Brinkum</name>
      <address>
        <city>Stuhr</city>
        <zip>28816</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 416) Praxis Dr. med Joachim Sauter</name>
      <address>
        <city>Wangen</city>
        <zip>88239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 412) MALU-Medizinische Studien GmbH</name>
      <address>
        <city>Wardenburg</city>
        <zip>26203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 424) Medislim GmbH</name>
      <address>
        <city>Weinheim</city>
        <zip>69469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 603) Ramathibodi Hospital, Mahid - Division of Infectious Disease</name>
      <address>
        <city>Bangkok</city>
        <zip>10160</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 606) Faculty of Tropical Medicine, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 608) Phramongkutklao Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 609) Division of Tropical Pediatrics</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 601) Faculty of Medicine, Chiang Mai University</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 607) Srinagarind Hospital Khon Kaen University</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 605) Golden Jubilee Medical Center</name>
      <address>
        <city>Nakhon Pathom</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>November 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2018</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>RNA Virus Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

